Literature DB >> 28069930

A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor.

Pengcheng Han1,2, Geidy Serrano3, Thomas G Beach3, Richard J Caselli4, Junxiang Yin1, Ningning Zhuang1, Jiong Shi1.   

Abstract

Neurofibrillary tangles (NFTs) represent products of insoluble tau protein in the brains of patients with Alzheimer disease (AD). The cerebrospinal fluid (CSF) tau level is a biomarker in AD diagnosis. The soluble portion of tau protein in brain parenchyma is presumably the source for CSF tau but this has not previously been quantified. We measured CSF tau and soluble brain tau at autopsy in temporal and frontal brain tissue samples from 7 cognitive normal, 12 mild cognitively impaired, and 19 AD subjects. Based on the measured brain soluble tau, we calculated the whole brain tau load and estimated tau secretion factor. Our results suggest that the increase in NFT in AD is likely attributable to post-translational processes; the increase in CSF tau in AD patients is due to an accelerated carrier-based secretion. Moreover, cognitive dysfunction assessed by final Mini-Mental State Examination scores correlated with the secretion factor but not with the soluble tau.
© 2017 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Soluble tau; Tau protein

Mesh:

Substances:

Year:  2017        PMID: 28069930      PMCID: PMC5901078          DOI: 10.1093/jnen/nlw105

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  34 in total

1.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

Review 2.  Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics.

Authors:  Anuradha Kalani; Alka Tyagi; Neetu Tyagi
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

3.  Tau transgenic mice as models for cerebrospinal fluid tau biomarkers.

Authors:  Donna M Barten; Gregory W Cadelina; Nina Hoque; Lynn B DeCarr; Valerie L Guss; Ling Yang; Sethu Sankaranarayanan; Paul D Wes; Marianne E Flynn; Jere E Meredith; Michael K Ahlijanian; Charles F Albright
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections.

Authors:  H Braak; E Braak
Journal:  Brain Pathol       Date:  1991-04       Impact factor: 6.508

5.  Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease.

Authors:  Michelle M Mielke; Norman J Haughey; Veera V R Bandaru; Henrik Zetterberg; Kaj Blennow; Ulf Andreasson; Sterling C Johnson; Carey E Gleason; Hanna M Blazel; Luigi Puglielli; Mark A Sager; Sanjay Asthana; Cynthia M Carlsson
Journal:  Neurobiol Aging       Date:  2014-05-27       Impact factor: 4.673

6.  Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Authors:  Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

Review 7.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

8.  Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.

Authors:  Chad A Dickey; Peter Ash; Natalia Klosak; Wing C Lee; Leonard Petrucelli; Michael Hutton; Christopher B Eckman
Journal:  Mol Neurodegener       Date:  2006-07-26       Impact factor: 14.195

9.  Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.

Authors:  Aiko Ishiki; Nobuyuki Okamura; Katsutoshi Furukawa; Shozo Furumoto; Ryuichi Harada; Naoki Tomita; Kotaro Hiraoka; Shoichi Watanuki; Yoichi Ishikawa; Tetsuro Tago; Yoshihito Funaki; Ren Iwata; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Hiroyuki Arai
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

10.  The importance of tau phosphorylation for neurodegenerative diseases.

Authors:  Wendy Noble; Diane P Hanger; Christopher C J Miller; Simon Lovestone
Journal:  Front Neurol       Date:  2013-07-01       Impact factor: 4.003

View more
  8 in total

1.  Clearance of intracellular tau protein from neuronal cells via VAMP8-induced secretion.

Authors:  Julie Pilliod; Alexandre Desjardins; Camille Pernègre; Hélène Jamann; Catherine Larochelle; Edward A Fon; Nicole Leclerc
Journal:  J Biol Chem       Date:  2020-10-22       Impact factor: 5.157

Review 2.  Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.

Authors:  Thomas K Karikari; Nicholas J Ashton; Gunnar Brinkmalm; Wagner S Brum; Andréa L Benedet; Laia Montoliu-Gaya; Juan Lantero-Rodriguez; Tharick Ali Pascoal; Marc Suárez-Calvet; Pedro Rosa-Neto; Kaj Blennow; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2022-05-18       Impact factor: 44.711

3.  Clearance of intracellular tau protein from neuronal cells via VAMP8-induced secretion.

Authors:  Julie Pilliod; Alexandre Desjardins; Camille Pernègre; Hélène Jamann; Catherine Larochelle; Edward A Fon; Nicole Leclerc
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

4.  Correlation between cognition and plasma noradrenaline level in Alzheimer's disease: a potential new blood marker of disease evolution.

Authors:  Laure-Elise Pillet; Camille Taccola; Justine Cotoni; Hervé Thiriez; Karine André; Romain Verpillot
Journal:  Transl Psychiatry       Date:  2020-07-03       Impact factor: 6.222

5.  A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging.

Authors:  Gary Arendash; Chuanhai Cao; Haitham Abulaban; Rob Baranowski; Gary Wisniewski; Lino Becerra; Ross Andel; Xiaoyang Lin; Xiaolin Zhang; David Wittwer; Jay Moulton; John Arrington; Amanda Smith
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 6.  Astrocytic Propagation of Tau in the Context of Alzheimer's Disease.

Authors:  Rebecca M Fleeman; Elizabeth A Proctor
Journal:  Front Cell Neurosci       Date:  2021-03-17       Impact factor: 5.505

Review 7.  Current Status of Clinical Trials on Tau Immunotherapies.

Authors:  Changyi Ji; Einar M Sigurdsson
Journal:  Drugs       Date:  2021-06-08       Impact factor: 11.431

8.  Nasal Extracts from Patients with Alzheimer's Disease Induce Tau Aggregates in a Cellular Model of Tau Propagation.

Authors:  Aslina Pahrudin Arrozi; Daijiro Yanagisawa; Tomoko Kato; Hiroyasu Akatsu; Yoshio Hashizume; Daita Kaneda; Ikuo Tooyama
Journal:  J Alzheimers Dis Rep       Date:  2021-04-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.